Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy

Documenti analoghi

• Correction to “Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma”
  Pubblicazione: (2025)
• Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK
  di: Andrea Kuhnl, et al.
  Pubblicazione: (2026)
• Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
  di: André Airosa Pardal, et al.
  Pubblicazione: (2025)
• Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma
  di: Tamer Othman, et al.
  Pubblicazione: (2024)
• Clinical outcomes of thoracic radiotherapy in combination with chemoimmunotherapy in elderly patients with extensive‐stage small cell lung cancer
  di: Jinmin Han, et al.
  Pubblicazione: (2026)